The FDA’s study of corrective direct-to-consumer (DTC) advertising will include 6,650 interviews of randomly assigned participants and include messaging about asthma in the first phase and weight-loss products in the second phase, according to a recent Federal Register notice covering the study’s information collection requirements. The agency is conducting the study to forward the development of empirical literature regarding the influences of corrective advertising. John Kamp, Executive Director, Coalition for Healthcare Communication, commented that this type of advertising “is an extraordinary remedy” that should be applied only to “violations that are extraordinary.” Read more.

Full Story:

Related Summaries